Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM).

@inproceedings{Ruers2010FinalRO,
  title={Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM).},
  author={T Ruers and Cornelis J A Punt and Frits van Coevorden and I. H. M. Borel Rinkes and Jonathan A Ledermann and Graeme Poston and Wolf O Bechstein and M. A. Lentz and Murielle Mauer and Bernard Nordlinger},
  year={2010}
}
3526 Background: In patients with unresectable CRC LM there is an increasing tendency to combine systemic chemotherapy (CT) with local tumour destruction by RFA. However, the benefit of this combined treatment has not yet been demonstrated. Methods: This randomised phase II study (ClinicalTrials.gov NCT00043004) evaluated the benefits of adding RFA to systemic CT in patients with ≤ 9 unresectable CRC LM and no extrahepatic disease. Between 2002 and 2007, 119 pts were randomised between CT alone… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 20 CITATIONS

The role of image-guided therapy in the management of colorectal cancer metastatic disease.

VIEW 2 EXCERPTS
CITES BACKGROUND & RESULTS